You are here

Study Comparing Remission Rates, in Patients With Major Depressive Disorder (MDD)

Last updated on November 30, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Haidari, Athens, 12461 Greece
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Major Depressive Disorder
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Outpatients

- 18-75 years old

- Patients diagnosed with MDD according to DSM IV without psychotic symptoms

- HAM-D17 > or = 18 on inclusion

- Patients receiving treatment for the first time or changing treatment based on their
doctor's decision

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects with potentially problematic compliance

- Subjects participating in an interventional trial within the last 3 months

NCT00770289
Pfizer
Completed
Study Comparing Remission Rates, in Patients With Major Depressive Disorder (MDD)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Major Depressive Disorder
NCT02548949
All Genders
19+
Years
Multiple Sites
Descriptive Information
Brief TitleStudy Comparing Remission Rates, in Patients With Major Depressive Disorder (MDD)
Official TitleOpen Label, Observational, Non-interventional Study for the Evaluation of Remission Rates in Patients With MDD Under Treatment With Various Anti-depressives
Brief SummaryTools known as 'depression scales 'are widely used as assessments to evaluate a patient's response to treatment. The purpose of this study is the evaluation of the remission rates for patients with MDD. The evaluation will involve the use of HAM-D 17, and HAM-D 7 questionnaires and the comparison of those questionnaires.
Detailed Description12 weeks random
Study TypeObservational
Study DesignObservational Model: Cohort
Target Follow-Up DurationNot Provided
BiospecimenNot Provided
Sampling MethodProbability Sample
Study PopulationPatients diagnosed with MDD who are either changing treatment or have never received treatment.
ConditionMajor Depressive Disorder
InterventionOther: Cohort
Cohort (Patients diagnosed with MDD who are either changing treatment or have never received treatment).
Study Groups/CohortsSingle group
Intervention: Other: Cohort
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment StatusCompleted
Actual Enrollment
 (submitted: July 15, 2009)
851
Original Estimated Enrollment
 (submitted: October 8, 2008)
1000
Actual Study Completion DateDecember 2009
Actual Primary Completion DateDecember 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Outpatients
  • 18-75 years old
  • Patients diagnosed with MDD according to DSM IV without psychotic symptoms
  • HAM-D17 > or = 18 on inclusion
  • Patients receiving treatment for the first time or changing treatment based on their doctor's decision

Exclusion Criteria:

  • Subjects with potentially problematic compliance
  • Subjects participating in an interventional trial within the last 3 months
Sex/Gender
Sexes Eligible for Study:All
Ages18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy VolunteersNo
ContactsContact information is only displayed when the study is recruiting subjects
Listed Location CountriesGreece
Removed Location Countries  
 
Administrative Information
NCT NumberNCT00770289
Other Study ID Numbers0600B-102374
B2411003 ( Other Identifier: Pfizer )
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing StatementNot Provided
Responsible PartyPfizer
Study SponsorPfizer
CollaboratorsNot Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateAugust 2012

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now